If patients who are also positive for anti-ARS antibodies were separately classified as having “anti-synthetase syndrome,” it would dilute the clinical characteristics of the anti-MDA5+ DM cohort, particularly in analyses related to RPILD and mortality risk. Here, IFIH1 is linked to dermatomyositis.